Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases

Surgery Today ◽  
1994 ◽  
Vol 24 (9) ◽  
pp. 819-822 ◽  
Author(s):  
Yoshiro Saikawa ◽  
Tetsuro Kubota ◽  
Toshiharu Furukawa ◽  
Koichiro Kumai ◽  
Keiichi Yoshino ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Mitomycin C ◽  
Combination Chemotherapy ◽  
Multiple Liver Metastases

scholarly journals Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment

In Vivo ◽  
2021 ◽  
Vol 35 (5) ◽  
pp. 2929-2935
Author(s):  
TSUTOMU NAMIKAWA ◽  
AKIRA MARUI ◽  
KEIICHIRO YOKOTA ◽  
YUKI FUJIEDA ◽  
MASAYA MUNEKAGE ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Combination Treatment ◽  
Conversion Surgery ◽  
Multiple Liver Metastases

5-fluorouracil, adriamycin, and mitomycin-c (fam) combination chemotherapy in the treatment of advanced gastric cancer

Cancer ◽  
1979 ◽  
Vol 44 (1) ◽  
pp. 42-47 ◽  
Author(s):  
John S. Macdonald ◽  
Paul V. Woolley ◽  
Tariyln Smythe ◽  
Winston Ueno ◽  
Daniel Hoth ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Mitomycin C ◽  
Combination Chemotherapy

scholarly journals A Case of Advanced Gastric Cancer with Liver Metastases Resected Successfully after S-1+CDDP Combination Chemotherapy

2011 ◽  
Vol 61 (4) ◽  
pp. 519-524
Author(s):  
Masaaki Arai ◽  
Ryo Ochiai ◽  
Keitaro Hirai ◽  
Yutaka Sunose ◽  
Hideaki Yokoo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Combination Chemotherapy

scholarly journals Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer

2018 ◽  
pp. 169-171
Author(s):  
T. A. Titova ◽  
N. S. Besova ◽  
V. A. Gorbunova ◽  
R. N. Nasyrova ◽  
A. A. Fedenko
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Phase Iii ◽  
Second Line ◽  
Her2 Positive ◽  
Second Line Chemotherapy ◽  
Multiple Liver Metastases ◽  
Line Chemotherapy

Gastric cancer is the third leading cause of cancer-related deaths worldwide. The prognosis of advanced gastric cancer remains poor despite therapeutic advances in recent decades. Several recent positive phase III trials established the efficacy of second-line chemotherapy for metastatic gastric cancer in prolonging overall survival. Many targeted-therapies failed to show a significant survival benefit in GC, only 2 of them are approved FDA: trastuzumab in the 1-st line treatment of HER2-positive gastric cancer and ramucirumab with or without paclitaxel as second line chemotherapy. The article presents the case of effective treatment of patient with Her2-negative advanced gastric cancer. A 76-year-old man had a moderately differentiated adenocarcinoma of gastric with synchronous multiple liver metastases. He received ramucirumab with paclitaxel as second -line chemotherapy. The size of the liver metastases was reduced and he maintained a partial response for one year. This clinical case report demonstrates that new option in the treatment of advanced gastric cancer can to allow our patients to live longer without losing the quality of life.

Sign in / Sign up

Export Citation Format

Share Document